- Home
- CABO vs MYGN Comparison
CABO vs MYGN Comparison
Compare CABO & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABO
- MYGN
- Stock Information
- Founded
- CABO 1980
- MYGN 1991
- Country
- CABO United States
- MYGN United States
- Employees
- CABO N/A
- MYGN N/A
- Industry
- CABO Cable & Other Pay Television Services
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CABO Telecommunications
- MYGN Health Care
- Exchange
- CABO Nasdaq
- MYGN Nasdaq
- Market Cap
- CABO 2.0B
- MYGN 2.0B
- IPO Year
- CABO N/A
- MYGN 1995
- Fundamental
- Price
- CABO $366.05
- MYGN $13.50
- Analyst Decision
- CABO Hold
- MYGN Hold
- Analyst Count
- CABO 5
- MYGN 11
- Target Price
- CABO $554.40
- MYGN $24.27
- AVG Volume (30 Days)
- CABO 72.9K
- MYGN 1.1M
- Earning Date
- CABO 02-20-2025
- MYGN 02-25-2025
- Dividend Yield
- CABO 3.27%
- MYGN N/A
- EPS Growth
- CABO 847.26
- MYGN N/A
- EPS
- CABO 38.05
- MYGN N/A
- Revenue
- CABO $1,604,144,000.00
- MYGN $823,600,000.00
- Revenue This Year
- CABO N/A
- MYGN $13.82
- Revenue Next Year
- CABO N/A
- MYGN $4.59
- P/E Ratio
- CABO $9.62
- MYGN N/A
- Revenue Growth
- CABO N/A
- MYGN 12.15
- 52 Week Low
- CABO $311.28
- MYGN $12.87
- 52 Week High
- CABO $574.53
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- CABO 41.82
- MYGN 32.61
- Support Level
- CABO $358.73
- MYGN $13.04
- Resistance Level
- CABO $372.49
- MYGN $13.77
- Average True Range (ATR)
- CABO 10.91
- MYGN 0.60
- MACD
- CABO -1.31
- MYGN 0.14
- Stochastic Oscillator
- CABO 44.24
- MYGN 24.51
About CABO Cable One Inc.
Cable One Inc is a telecommunications company. It derives revenue from the provision of broadband, voice, and video services to residential and business customers. From a product perspective, the majority of revenue is sourced from data and video services. This revenue is subscription-based and billed monthly. The company also offers Sparklight TV, an internet protocol-based (IPTV) video service that allows customers with Sparklight TV app to stream video channels from the cloud. The company also derives advertising revenue from selling airtime on its video channels. Voice services are offered over Internet protocols. The company owns a telecommunications infrastructure.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.